We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy in patients with Parkinson disease dementia (PDD) to determine whether cognitive improvements would be reflected in changes of cerebral metabolic patterns, thus offering insight into the neural substrate of cognitive dysfunction in patients with PDD. METHODS: We performed a serial PET study before (baseline) and after ChEI therapy on 10 patients with PDD, using statistical parametric mapping. Additionally, covariance analysis was performed to extract regions in which increased change in regional cerebral metabolism correlated significantly with increased Mini-Mental State Examination scores. RESULTS: The statistical parametric mapping anal...
Cerebral blood flow (CBF) and glucose consumption (GC) are both tracers of brain metabolic activity ...
OBJECTIVE: To investigate the changes in cerebral glucose metabolism in patients with posttraumatic ...
Cholinergic dysfunction plays a prominent role in cognitive impairment in Parkinson's disease (PD). ...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
$\textbf{Objective}$ To assess reductions of cerebral glucose metabolism in Parkinson’s disease (PD)...
Summary Several evidences suggest that cholinergic deficits may significantly contribute to dementi...
BACKGROUND: Half of Parkinson's disease (PD) patients with mild cognitive impairment (MCI) develop d...
PURPOSE:To characterize cerebral glucose metabolism associated with different cognitive states in Pa...
Despite controversial clinicopathological distinctions between Parkinson's disease with dementia (PD...
Objective: To investigate muscarinic M1/M4 cholinergic networks in Parkinson disease dementia (PDD) ...
PURPOSE: Cognitive impairment (CI) in Parkinson's disease (PD) is associated with a widespread reduc...
Abstract: Cholinesterase (ChE) inhibitors improve or stabilize cognitive impairment in patients wit...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
OBJECTIVE: To characterize brain metabolic changes associated with mild cognitive impairment (MCI) ...
Cerebral blood flow (CBF) and glucose consumption (GC) are both tracers of brain metabolic activity ...
OBJECTIVE: To investigate the changes in cerebral glucose metabolism in patients with posttraumatic ...
Cholinergic dysfunction plays a prominent role in cognitive impairment in Parkinson's disease (PD). ...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
$\textbf{Objective}$ To assess reductions of cerebral glucose metabolism in Parkinson’s disease (PD)...
Summary Several evidences suggest that cholinergic deficits may significantly contribute to dementi...
BACKGROUND: Half of Parkinson's disease (PD) patients with mild cognitive impairment (MCI) develop d...
PURPOSE:To characterize cerebral glucose metabolism associated with different cognitive states in Pa...
Despite controversial clinicopathological distinctions between Parkinson's disease with dementia (PD...
Objective: To investigate muscarinic M1/M4 cholinergic networks in Parkinson disease dementia (PDD) ...
PURPOSE: Cognitive impairment (CI) in Parkinson's disease (PD) is associated with a widespread reduc...
Abstract: Cholinesterase (ChE) inhibitors improve or stabilize cognitive impairment in patients wit...
Reduction in the regional cerebral metabolic rate for glucose (rCMRglc) in the parietal and temporal...
OBJECTIVE: To characterize brain metabolic changes associated with mild cognitive impairment (MCI) ...
Cerebral blood flow (CBF) and glucose consumption (GC) are both tracers of brain metabolic activity ...
OBJECTIVE: To investigate the changes in cerebral glucose metabolism in patients with posttraumatic ...
Cholinergic dysfunction plays a prominent role in cognitive impairment in Parkinson's disease (PD). ...